TAKE DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.11×2.46×50.77×1.01×2.22×
−3.49×−2.30×−0.10×5.55×1.26×
−2.1%−3.5%—−32.5%−19.0%
1.49×1.49×0.00×0.42×0.84×
1.17×1.17×1.78×−9.93×2.07×
26.4%34.9%—760.4%−92.1%
42.1%42.1%643.0%−239.9%−92.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TAKE₹11.06

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹164 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×2.221.0150.772.462.11
Interest Burden (Pretax/EBIT) ×1.265.55-0.10-2.30-3.49
EBIT Margin %-18.97-32.54—-3.55-2.05
Asset Turnover ×0.840.420.001.491.49
Financial Leverage (Assets/Equity) ×2.07-9.931.781.171.17
ROE (5-step product, year-end total equity) %-92.11760.37—34.8826.41
ROE (owners' profit / average owners' equity) %-92.32-239.89642.9942.1142.11
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.